Personalized medicine in multiple sclerosis: hope or reality?

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Personalized Medicine

Background:

• Multiple sclerosis (MS) is a heterogeneous neurological disease with variable clinical courses and treatment responses.
• Current classification of MS activity and treatment response relies on clinical features and magnetic resonance imaging (MRI), which are effective at a group level but insufficient for individual patient prediction.
• There is a critical need for advanced biomarkers to improve prognostic accuracy and personalize treatment strategies in MS.

Purpose of the Study:

• To highlight the necessity for novel biomarkers in multiple sclerosis (MS).
• To emphasize the limitations of current diagnostic and prognostic tools in predicting individual patient outcomes.
• To advocate for the validation of promising molecular and imaging targets in large-scale, prospective studies.

Main Methods:

• Review of current clinical and imaging-based classification methods for multiple sclerosis.
• Identification of limitations in predicting individual patient prognosis and treatment response.
• Discussion of emerging biomarkers from basic and clinical research.

Main Results:

• Existing classification methods for multiple sclerosis (MS) show limitations in predicting individual patient outcomes due to disease heterogeneity.
• Promising new biomarker targets have been identified through ongoing research.
• The accuracy and utility of these novel markers require validation in extensive, prospectively collected patient data.

Conclusions:

• Personalized treatment approaches are essential for managing the heterogeneity of multiple sclerosis (MS).
• Novel biomarkers are crucial for improving the prediction of prognosis and treatment response in individual MS patients.
• Prospective validation of identified biomarkers in large patient cohorts is the critical next step for clinical implementation.